Vioxx was easier on the stomach than aspirin, but it cost more.
It was not stopped earlier because trial results did not find increased risk in the first 18 months of the trial, the FDA said.
Meanwhile, the European Medicines Agency in London announced it would review drugs similar to Vioxx.